Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study.

Autor: Beckmann K; UniSA Cancer Research Institute, University of South Australia, Adelaide, Australia. Kerri.beckmann@kcl.ac.uk.; School of Cancer and Pharmaceutical Studies, Translational Oncology & Urology Research (TOUR), King's College London, London, UK. Kerri.beckmann@kcl.ac.uk., Russell B; School of Cancer and Pharmaceutical Studies, Translational Oncology & Urology Research (TOUR), King's College London, London, UK., Josephs D; School of Cancer and Pharmaceutical Studies, Translational Oncology & Urology Research (TOUR), King's College London, London, UK., Garmo H; School of Cancer and Pharmaceutical Studies, Translational Oncology & Urology Research (TOUR), King's College London, London, UK.; Regional Cancer Centre Uppsala, Uppsala University Hospital, Uppsala, Sweden., Haggstrom C; Department of Biobank Research, Umea University, Umea, Sweden.; Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden., Holmberg L; School of Cancer and Pharmaceutical Studies, Translational Oncology & Urology Research (TOUR), King's College London, London, UK.; Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden., Stattin P; Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden., Van Hemelrijck M; School of Cancer and Pharmaceutical Studies, Translational Oncology & Urology Research (TOUR), King's College London, London, UK.; Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Adolfsson J; CLINTEC-department, Karolinska Institutet, Stockholm, Sweden.
Jazyk: angličtina
Zdroj: BMC cancer [BMC Cancer] 2019 Jun 21; Vol. 19 (1), pp. 612. Date of Electronic Publication: 2019 Jun 21.
DOI: 10.1186/s12885-019-5846-3
Abstrakt: Background: Whether chronic inflammation increases prostate cancer risk remains unclear. This study investigated whether chronic inflammatory diseases (CID) or anti-inflammatory medication use (AIM) were associated with prostate cancer risk.
Methods: Fifty-five thousand nine hundred thirty-seven cases (all prostate cancer, 2007-2012) and 279,618 age-matched controls were selected from the Prostate Cancer Database Sweden. CIDs and AIMs was determined from national patient and drug registers. Associations were investigated using conditional logistic regression, including for disease/drug subtypes and exposure length/dose.
Results: Men with a history of any CID had slightly increased risk of any prostate cancer diagnosis (OR: 1.08; 95%CI: 1.04-1.12) but not 'unfavourable' (high-risk or advanced) prostate cancer. Generally, risk of prostate cancer was highest for shorter exposure times. However, a positive association was observed for asthma > 5 years before prostate cancer diagnosis (OR: 1.21; 95%CI: 1.05-1.40). Risk of prostate cancer was increased with prior use of any AIMs (OR: 1.26; 95%CI: 1.24-1.29). A positive trend with increasing cumulative dose was only observed for inhaled glucocorticoids (p < 0.011).
Conclusion: Detection bias most likely explains the elevated risk of prostate cancer with prior history of CIDs or use of AIMs, given the higher risk immediately after first CID event and lack of dose response. However, findings for length of time with asthma and dose of inhaled glucocorticoids suggest that asthma may increase risk of prostate cancer through other pathways.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje